Alcon Research

ALC

$11.61B

Large Cap

NASDAQOphthalmic GoodsOphthalmology🇺🇸EuropeFORT WORTH25.6K employees

Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.

Website

Drugs in Pipeline

122

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 10, 2026

Market Overview

Stock performance and key metrics

ALC News

Catalyst Timeline

2 upcoming, 0 past

EarningsNext

ALC Earnings Report

Aug 10, 2026Confirmed

EPS Est: $0.77 | FQ end 2026-06 | Call: 2026-08-11 07:00:00

1 more catalyst beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

Drug Pipeline

Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution

Phase 3

Open-angle Glaucoma

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Phase 3

Allergic Conjunctivitis

Travoprost 0.004% PQ ophthalmic solution

Phase 3

Pediatric Glaucoma

Olopatadine Hydrochloride Ophthalmic Solution Vehicle

Phase 3

Allergic Conjunctivitis

Moxifloxacin ophthalmic solution, 0.5%

Phase 3

Bacterial Conjunctivitis

Tobradex ST

Phase 3

Blepharitis

Aflibercept ophthalmic solution

Phase 3

Neovascular Age-Related Macular Degeneration

Nepafenac 1mg/ml eye drops, suspension

Phase 3

Cataracts

Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension

Phase 3

Open-angle Glaucoma

Travoprost ophthalmic solution, 0.003%

Phase 3

Open-Angle Glaucoma

Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution

Phase 3

Open-Angle Glaucoma

Brimonidine tartrate ophthalmic solution, 0.2%

Phase 3

Open-Angle Glaucoma

Triamcinolone Acetonide Injectable Suspension

Phase 3

Vitrectomy

Nepafenac Ophthalmic Suspension, 0.3%

Phase 3

Non-Proliferative Diabetic Retinopathy

Apraclonidine Hydrochloride Ophthalmic Solution

Phase 3

Ocular Redness

BETOPTIC S (betaxolol HCl)

Phase 3

Glaucoma

quinolone

Phase 3

Bacterial Conjunctivitis

Prednisolone acetate

Phase 3

Non-Proliferative Diabetic Retinopathy

AL-3862+timolol ophthalmic suspension

Phase 3

Glaucoma

Nepafenac ophthalmic suspension, 0.1% (NEVANAC)

Phase 3

Macular Edema

Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%

Phase 3

Bacterial Conjunctivitis

Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)

Phase 3

Glaucoma

Travoprost/Timolol Maleate Fixed Combination solution

Phase 3

Open-angle Glaucoma

Dexamethasone phosphate otic solution

Phase 3

Acute Otitis Externa

Latanoprost ophthalmic solution 0.005% (XALATAN®)

Phase 3

Open-angle Glaucoma

Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension

Phase 3

Open-angle Glaucoma

Olopatadine Hydrochloride Nasal Spray 0.6%

Phase 3

Allergic Rhinitis

Olopatadine 0.6% nasal spray

Phase 3

Perennial Allergic Rhinitis

Travatan

Phase 3

Glaucoma, Open-angle

Olopatadine Hydrochloride Ophthalmic Solution, 0.1%

Phase 3

Allergic Conjunctivitis

AL-60371 Vehicle

Phase 3

Acute Otitis Externa

AL-60371, 0.3% Otic Suspension

Phase 3

Acute Otitis Externa

Timolol maleate ophthalmic solution, 0.5%

Phase 3

Open-angle Glaucoma

Anecortave Acetate Sterile Suspension, 60 mg/mL

Phase 3

Open-angle Glaucoma

BSS Plus

Phase 3

Cataract

Latanoprost 0.005% Ophthalmic Solution (XALATAN)

Phase 3

Open-Angle Glaucoma

Nepafenac Ophthalmic Suspension, 0.1%

Phase 3

Cataract

Rimexolone

Phase 3

Dry Eye

AL-4943A Ophthalmic Solution Vehicle

Phase 3

Allergic Conjunctivitis

Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Phase 3

Open-Angle Glaucoma

AL-4943A ophthalmic solution

Phase 3

Allergic Conjunctivitis

Ofloxacin otic solution

Phase 3

Acute Otitis Media

Difluprednate 0.05% ophthalmic emulsion

Phase 3

Endogenous Anterior Uveitis

Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution

Phase 3

Glaucoma, Open-angle

Brinzolamide 1% ophthalmic suspension

Phase 3

Open-Angle Glaucoma

Difluprednate ophthalmic emulsion, 0.05%

Phase 3

Cataracts

Travoprost 0.004%/Timolol 0.5%

Phase 3

Open-angle Glaucoma

Travoprost 0.004% with and without BAK

Phase 3

Open-angle Glaucoma

Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension

Phase 3

Cataract

Travoprost, Investigational

Phase 3

Open-angle Glaucoma

Next Generation Ophthalmic Irrigating Solution (NGOIS)

Phase 3

Cataract

Tobramycin 0.3%/Dexamethasone 0.05%

Phase 3

Ocular Inflammation Associated With Blepharaconjunctivitis

Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension

Phase 3

Open-Angle Glaucoma

Brinzolamide ophthalmic suspension, 1%

Phase 3

Open-Angle Glaucoma

0.003% AR-15512 ophthalmic solution

Phase 3

Dry Eye Disease

Anecortave Acetate Sterile Suspension, 75 mg/mL

Phase 3

Open-angle Glaucoma

anecortave acetate

Phase 3

Macular Degeneration

Tobradex AF

Phase 3

Cataract

EXE844 Sterile Otic Suspension, 0.3%

Phase 3

Otitis Media With Effusion in Children

Travoprost (0.004%)

Phase 3

Glaucoma, Open-Angle

Sodium Hyaluronate Ophthalmic Solution, 0.18%

Phase 3

Dry Eye Syndrome

Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%

Phase 3

Bacterial Conjunctivitis

Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension

Phase 3

Open-Angle Glaucoma

Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension

Phase 3

Open-Angle Glaucoma

Alcon Investigational Agent

Phase 3

Open-Angle Glaucoma

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

Phase 3

Open-angle Glaucoma

Brimonidine Tartrate Ophthalmic Solution

Phase 3

Open-Angle Glaucoma

Latanoprost (0.005%)

Phase 3

Glaucoma, Angle-Closure

0.003% AR-15512

Phase 3

Dry Eye Disease

Nepafenac ophthalmic solution 0.1%

Phase 3

Cataract

Anecortave Acetate Sterile Suspension, 30 mg/mL

Phase 3

Macular Degeneration

FID 123320 Ophthalmic Solution

Phase 3

Ocular Redness

Brolucizumab ophthalmic solution

Phase 3

Neovascular Age-Related Macular Degeneration

Moxidex otic solution

Phase 3

Acute Otitis Media

IOP Lowering Medications

Phase 3

Open-Angle Glaucoma

Olopatadine Hydrochloride Ophthalmic Solution 0.2%

Phase 3

Allergic Conjunctivitis

Moxifloxacin otic solution

Phase 3

Acute Otitis Media

Anecortave Acetate 15 mg sterile suspension

Phase 3

Macular Degeneration

Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution

Phase 3

Open Angle Glaucoma

BETAXON (levobetaxolol HCl)

Phase 3

Glaucoma

Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution

Phase 3

Ocular Hypertension

Travoprost APS 40 micrograms/ml eye drop solution

Phase 3

Open Angle Glaucoma

Travoprost

Phase 3

Glaucoma, Open-Angle

Ocriplasmin

Phase 3

Symptomatic Vitreomacular Adhesion

LME636 60 mg/mL ophthalmic solution

Phase 2

Acute Anterior Uveitis

Anecortave acetate 30 mg

Phase 2

AMD

AL-3789 Sterile Suspension

Phase 2

Open-angle Glaucoma

AL-38583 ophthalmic solution

Phase 2

Allergic Conjunctivitis

Ranibizumab 0.5 mg

Phase 2

Exudative Age-Related Macular Degeneration

Travoprost ophthalmic solution, 0.0008%

Phase 2

Open-angle Glaucoma

Xalatan

Phase 2

Open-Angle Glaucoma

AL-37807 ophthalmic suspension, 0.1%

Phase 2

Open-Angle Glaucoma

Aflibercept

Phase 2

Exudative Age-Related Macular Degeneration

Travoprost/brinzolamide

Phase 2

Open-angle Glaucoma

Combination IOP Lowering Therapy

Phase 2

Glaucoma, Open-angle

Anecortave Acetate Sterile Suspension, 6 mg/mL

Phase 2

Eye Diseases

LHA510 ophthalmic suspension

Phase 2

Exudative Age-Related Macular Degeneration

AR-17043 Ophthalmic Solution

Phase 2

Open Angle Glaucoma

AL-39256 Ophthalmic Suspension, 1%

Phase 2

Open-Angle Glaucoma

AL-39324 ophthalmic suspension

Phase 2

Age Related Macular Degeneration

Travoprost Ophthalmic Solution, 0.00013%

Phase 2

Open-angle Glaucoma

Travoprost ophthalmic solution (new formulation)

Phase 2

Ocular Hypertension

Brolucizumab 3 mg/50 μL

Phase 2

Neovascular Age-Related Macular Degeneration

AL-53817 Ophthalmic Solution, 0.1%

Phase 2

Allergic Conjunctivitis

Dose Level A / Brinzolamide 1% ophthalmic suspension

Phase 2

Glaucoma

ESBA1008 solution

Phase 2

Exudative Age-Related Macular Degeneration

ESBA105 ophthalmic solution

Phase 2

Eyes Dry Chronic

MGV354 ophthalmic suspension

Phase 2

Ocular Hypertension

AR-14034 SR implant lower dose

Phase 2

Neovascular Age-related Macular Degeneration (nAMD)

AL-12182 0.003% Ophthalmic Solution

Phase 2

Open-angle Glaucoma

AL-37807 Ophthalmic Suspension, 1.0%

Phase 2

Open-angle Glaucoma

Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel

Phase 2

Dry Eye

Travoprost Vehicle

Phase 2

Open-angle Glaucoma (OAG)

AL-78898A

Phase 2

Exudative Age-Related Macular Degeneration

AL-37807

Phase 2

Open-Angle Glaucoma

Brinzolamide/Timolol

Phase 2

Open-angle Glaucoma

AL-38583 ophthalmic solution 0.05%

Phase 2

Dry Eye

Glaucoma therapy

Phase 2

Open-Angle Glaucoma

AL-54478 0.005%

Phase 2

Open-angle Glaucoma (OAG)

CLG561

Phase 2

Geographic Atrophy

Hydroxypropyl Guar Galactomannan

Phase 2

Dry Eye Disease

LME636 ophthalmic solution

Phase 2

Dry Eye

Drug Name	Phase	Indication	Designations	Patent
Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution	Phase 3	Open-angle Glaucoma	-	-
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%	Phase 3	Allergic Conjunctivitis	-	-
Travoprost 0.004% PQ ophthalmic solution	Phase 3	Pediatric Glaucoma	-	-
Olopatadine Hydrochloride Ophthalmic Solution Vehicle	Phase 3	Allergic Conjunctivitis	-	-
Moxifloxacin ophthalmic solution, 0.5%	Phase 3	Bacterial Conjunctivitis	-	-
Tobradex ST	Phase 3	Blepharitis	-	-
Aflibercept ophthalmic solution	Phase 3	Neovascular Age-Related Macular Degeneration	-	-
Nepafenac 1mg/ml eye drops, suspension	Phase 3	Cataracts	-	-
Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension	Phase 3	Open-angle Glaucoma	-	-
Travoprost ophthalmic solution, 0.003%	Phase 3	Open-Angle Glaucoma	-	-
Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution	Phase 3	Open-Angle Glaucoma	-	-
Brimonidine tartrate ophthalmic solution, 0.2%	Phase 3	Open-Angle Glaucoma	-	-
Triamcinolone Acetonide Injectable Suspension	Phase 3	Vitrectomy	-	-
Nepafenac Ophthalmic Suspension, 0.3%	Phase 3	Non-Proliferative Diabetic Retinopathy	-	-
Apraclonidine Hydrochloride Ophthalmic Solution	Phase 3	Ocular Redness	-	-
BETOPTIC S (betaxolol HCl)	Phase 3	Glaucoma	-	-
quinolone	Phase 3	Bacterial Conjunctivitis	-	-
Prednisolone acetate	Phase 3	Non-Proliferative Diabetic Retinopathy	-	-
AL-3862+timolol ophthalmic suspension	Phase 3	Glaucoma	-	-
Nepafenac ophthalmic suspension, 0.1% (NEVANAC)	Phase 3	Macular Edema	-	-
Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%	Phase 3	Bacterial Conjunctivitis	-	-
Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)	Phase 3	Glaucoma	-	-
Travoprost/Timolol Maleate Fixed Combination solution	Phase 3	Open-angle Glaucoma	-	-
Dexamethasone phosphate otic solution	Phase 3	Acute Otitis Externa	-	-
Latanoprost ophthalmic solution 0.005% (XALATAN®)	Phase 3	Open-angle Glaucoma	-	-
Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension	Phase 3	Open-angle Glaucoma	-	-
Olopatadine Hydrochloride Nasal Spray 0.6%	Phase 3	Allergic Rhinitis	-	-
Olopatadine 0.6% nasal spray	Phase 3	Perennial Allergic Rhinitis	-	-
Travatan	Phase 3	Glaucoma, Open-angle	-	-
Olopatadine Hydrochloride Ophthalmic Solution, 0.1%	Phase 3	Allergic Conjunctivitis	-	-
AL-60371 Vehicle	Phase 3	Acute Otitis Externa	-	-
AL-60371, 0.3% Otic Suspension	Phase 3	Acute Otitis Externa	-	-
Timolol maleate ophthalmic solution, 0.5%	Phase 3	Open-angle Glaucoma	-	-
Anecortave Acetate Sterile Suspension, 60 mg/mL	Phase 3	Open-angle Glaucoma	-	-
BSS Plus	Phase 3	Cataract	-	-
Latanoprost 0.005% Ophthalmic Solution (XALATAN)	Phase 3	Open-Angle Glaucoma	-	-
Nepafenac Ophthalmic Suspension, 0.1%	Phase 3	Cataract	-	-
Rimexolone	Phase 3	Dry Eye	-	-
AL-4943A Ophthalmic Solution Vehicle	Phase 3	Allergic Conjunctivitis	-	-
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension	Phase 3	Open-Angle Glaucoma	-	-
AL-4943A ophthalmic solution	Phase 3	Allergic Conjunctivitis	-	-
Ofloxacin otic solution	Phase 3	Acute Otitis Media	-	-
Difluprednate 0.05% ophthalmic emulsion	Phase 3	Endogenous Anterior Uveitis	-	-
Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution	Phase 3	Glaucoma, Open-angle	-	-
Brinzolamide 1% ophthalmic suspension	Phase 3	Open-Angle Glaucoma	-	-
Difluprednate ophthalmic emulsion, 0.05%	Phase 3	Cataracts	-	-
Travoprost 0.004%/Timolol 0.5%	Phase 3	Open-angle Glaucoma	-	-
Travoprost 0.004% with and without BAK	Phase 3	Open-angle Glaucoma	-	-
Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension	Phase 3	Cataract	-	-
Travoprost, Investigational	Phase 3	Open-angle Glaucoma	-	-
Next Generation Ophthalmic Irrigating Solution (NGOIS)	Phase 3	Cataract	-	-
Tobramycin 0.3%/Dexamethasone 0.05%	Phase 3	Ocular Inflammation Associated With Blepharaconjunctivitis	-	-
Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension	Phase 3	Open-Angle Glaucoma	-	-
Brinzolamide ophthalmic suspension, 1%	Phase 3	Open-Angle Glaucoma	-	-
0.003% AR-15512 ophthalmic solution	Phase 3	Dry Eye Disease	-	-
Anecortave Acetate Sterile Suspension, 75 mg/mL	Phase 3	Open-angle Glaucoma	-	-
anecortave acetate	Phase 3	Macular Degeneration	-	-
Tobradex AF	Phase 3	Cataract	-	-
EXE844 Sterile Otic Suspension, 0.3%	Phase 3	Otitis Media With Effusion in Children	-	-
Travoprost (0.004%)	Phase 3	Glaucoma, Open-Angle	-	-
Sodium Hyaluronate Ophthalmic Solution, 0.18%	Phase 3	Dry Eye Syndrome	-	-
Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%	Phase 3	Bacterial Conjunctivitis	-	-
Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension	Phase 3	Open-Angle Glaucoma	-	-
Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension	Phase 3	Open-Angle Glaucoma	-	-
Alcon Investigational Agent	Phase 3	Open-Angle Glaucoma	-	-
Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)	Phase 3	Open-angle Glaucoma	-	-
Brimonidine Tartrate Ophthalmic Solution	Phase 3	Open-Angle Glaucoma	-	-
Latanoprost (0.005%)	Phase 3	Glaucoma, Angle-Closure	-	-
0.003% AR-15512	Phase 3	Dry Eye Disease	-	-
Nepafenac ophthalmic solution 0.1%	Phase 3	Cataract	-	-
Anecortave Acetate Sterile Suspension, 30 mg/mL	Phase 3	Macular Degeneration	-	-
FID 123320 Ophthalmic Solution	Phase 3	Ocular Redness	-	-
Brolucizumab ophthalmic solution	Phase 3	Neovascular Age-Related Macular Degeneration	-	-
Moxidex otic solution	Phase 3	Acute Otitis Media	-	-
IOP Lowering Medications	Phase 3	Open-Angle Glaucoma	-	-
Olopatadine Hydrochloride Ophthalmic Solution 0.2%	Phase 3	Allergic Conjunctivitis	-	-
Moxifloxacin otic solution	Phase 3	Acute Otitis Media	-	-
Anecortave Acetate 15 mg sterile suspension	Phase 3	Macular Degeneration	-	-
Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution	Phase 3	Open Angle Glaucoma	-	-
BETAXON (levobetaxolol HCl)	Phase 3	Glaucoma	-	-
Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution	Phase 3	Ocular Hypertension	-	-
Travoprost APS 40 micrograms/ml eye drop solution	Phase 3	Open Angle Glaucoma	-	-
Travoprost	Phase 3	Glaucoma, Open-Angle	-	-
Ocriplasmin	Phase 3	Symptomatic Vitreomacular Adhesion	-	-
LME636 60 mg/mL ophthalmic solution	Phase 2	Acute Anterior Uveitis	-	-
Anecortave acetate 30 mg	Phase 2	AMD	-	-
AL-3789 Sterile Suspension	Phase 2	Open-angle Glaucoma	-	-
AL-38583 ophthalmic solution	Phase 2	Allergic Conjunctivitis	-	-
Ranibizumab 0.5 mg	Phase 2	Exudative Age-Related Macular Degeneration	-	-
Travoprost ophthalmic solution, 0.0008%	Phase 2	Open-angle Glaucoma	-	-
Xalatan	Phase 2	Open-Angle Glaucoma	-	-
AL-37807 ophthalmic suspension, 0.1%	Phase 2	Open-Angle Glaucoma	-	-
Aflibercept	Phase 2	Exudative Age-Related Macular Degeneration	-	-
Travoprost/brinzolamide	Phase 2	Open-angle Glaucoma	-	-
Combination IOP Lowering Therapy	Phase 2	Glaucoma, Open-angle	-	-
Anecortave Acetate Sterile Suspension, 6 mg/mL	Phase 2	Eye Diseases	-	-
LHA510 ophthalmic suspension	Phase 2	Exudative Age-Related Macular Degeneration	-	-
AR-17043 Ophthalmic Solution	Phase 2	Open Angle Glaucoma	-	-
AL-39256 Ophthalmic Suspension, 1%	Phase 2	Open-Angle Glaucoma	-	-
AL-39324 ophthalmic suspension	Phase 2	Age Related Macular Degeneration	-	-
Travoprost Ophthalmic Solution, 0.00013%	Phase 2	Open-angle Glaucoma	-	-
Travoprost ophthalmic solution (new formulation)	Phase 2	Ocular Hypertension	-	-
Brolucizumab 3 mg/50 μL	Phase 2	Neovascular Age-Related Macular Degeneration	-	-
AL-53817 Ophthalmic Solution, 0.1%	Phase 2	Allergic Conjunctivitis	-	-
Dose Level A / Brinzolamide 1% ophthalmic suspension	Phase 2	Glaucoma	-	-
ESBA1008 solution	Phase 2	Exudative Age-Related Macular Degeneration	-	-
ESBA105 ophthalmic solution	Phase 2	Eyes Dry Chronic	-	-
MGV354 ophthalmic suspension	Phase 2	Ocular Hypertension	-	-
AR-14034 SR implant lower dose	Phase 2	Neovascular Age-related Macular Degeneration (nAMD)	-	-
AL-12182 0.003% Ophthalmic Solution	Phase 2	Open-angle Glaucoma	-	-
AL-37807 Ophthalmic Suspension, 1.0%	Phase 2	Open-angle Glaucoma	-	-
Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel	Phase 2	Dry Eye	-	-
Travoprost Vehicle	Phase 2	Open-angle Glaucoma (OAG)	-	-
AL-78898A	Phase 2	Exudative Age-Related Macular Degeneration	-	-
AL-37807	Phase 2	Open-Angle Glaucoma	-	-
Brinzolamide/Timolol	Phase 2	Open-angle Glaucoma	-	-
AL-38583 ophthalmic solution 0.05%	Phase 2	Dry Eye	-	-
Glaucoma therapy	Phase 2	Open-Angle Glaucoma	-	-
AL-54478 0.005%	Phase 2	Open-angle Glaucoma (OAG)	-	-
CLG561	Phase 2	Geographic Atrophy	-	-
Hydroxypropyl Guar Galactomannan	Phase 2	Dry Eye Disease	-	-
LME636 ophthalmic solution	Phase 2	Dry Eye	-	-

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

What is in Alcon Research's drug pipeline?→

CatalystAlert tracks 122 drug candidates in Alcon Research's (ALC) pipeline across Phase 3, Phase 2. Its lead program is Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Alcon Research's next FDA catalyst?→

Alcon Research's (ALC) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ALC biotech catalysts?→

Add ALC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alcon Research's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Alcon Research

Market Overview

ALC News

Catalyst Timeline

ALC Earnings Report

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals

Frequently asked questions